Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17142212rdf:typepubmed:Citationlld:pubmed
pubmed-article:17142212lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:17142212lifeskim:mentionsumls-concept:C0016410lld:lifeskim
pubmed-article:17142212lifeskim:mentionsumls-concept:C0025677lld:lifeskim
pubmed-article:17142212lifeskim:mentionsumls-concept:C1314792lld:lifeskim
pubmed-article:17142212lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:17142212lifeskim:mentionsumls-concept:C0003737lld:lifeskim
pubmed-article:17142212pubmed:issue5lld:pubmed
pubmed-article:17142212pubmed:dateCreated2006-12-4lld:pubmed
pubmed-article:17142212pubmed:abstractTextThe purpose of this examination was to observe the effects of folic acid (FA) on methotrexate (MTX)-induced derangements in the fallopian tubes. Investigators in this study sought to explore whether MTX-induced dysfunction in the fallopian tubes would be lessened by the addition of FA to MTX treatment. For this study, 18 albino Wistar rats were randomly divided into 6 groups, each of which comprised 3 rats; 0.1 mg/kg FA, 1 mg/kg MTX + 0.1 mg/kg FA, 5 mg/kg MTX + 0.1 mg/kg FA, 1 mg/kg MTX, and 5 mg/kg MTX were given to groups 2, 3, 4, 5,and 6, respectively; group 1 was the control group. After MTX injection, fallop-ian tube samples from all groups were prepared for examination under electron microscopy. The findings observed in groups 1 and 2 were similar. The level of cellular destruction was greater with the higher doses of MTX without FA; in particular, loss of cilia in the epithelium was prominent in groups 5 and 6. However, there was less cellular destruction observed in groups 3 and 4 than in groups 5 and 6. As a result, the addition of FA should not be overlooked, even when a single-dose MTX regimen is chosen for the treatment of patients with unruptured ectopic pregnancy.lld:pubmed
pubmed-article:17142212pubmed:languageenglld:pubmed
pubmed-article:17142212pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17142212pubmed:citationSubsetTlld:pubmed
pubmed-article:17142212pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17142212pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17142212pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17142212pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17142212pubmed:statusMEDLINElld:pubmed
pubmed-article:17142212pubmed:issn0741-238Xlld:pubmed
pubmed-article:17142212pubmed:authorpubmed-author:BayramMerihMlld:pubmed
pubmed-article:17142212pubmed:authorpubmed-author:ErcanZ...lld:pubmed
pubmed-article:17142212pubmed:authorpubmed-author:OzogulCandanClld:pubmed
pubmed-article:17142212pubmed:authorpubmed-author:BayramOrhanOlld:pubmed
pubmed-article:17142212pubmed:authorpubmed-author:DilekozErginElld:pubmed
pubmed-article:17142212pubmed:authorpubmed-author:SoyerCananClld:pubmed
pubmed-article:17142212pubmed:issnTypePrintlld:pubmed
pubmed-article:17142212pubmed:volume23lld:pubmed
pubmed-article:17142212pubmed:ownerNLMlld:pubmed
pubmed-article:17142212pubmed:authorsCompleteYlld:pubmed
pubmed-article:17142212pubmed:pagination772-7lld:pubmed
pubmed-article:17142212pubmed:meshHeadingpubmed-meshheading:17142212...lld:pubmed
pubmed-article:17142212pubmed:meshHeadingpubmed-meshheading:17142212...lld:pubmed
pubmed-article:17142212pubmed:meshHeadingpubmed-meshheading:17142212...lld:pubmed
pubmed-article:17142212pubmed:meshHeadingpubmed-meshheading:17142212...lld:pubmed
pubmed-article:17142212pubmed:meshHeadingpubmed-meshheading:17142212...lld:pubmed
pubmed-article:17142212pubmed:meshHeadingpubmed-meshheading:17142212...lld:pubmed
pubmed-article:17142212pubmed:meshHeadingpubmed-meshheading:17142212...lld:pubmed
pubmed-article:17142212pubmed:meshHeadingpubmed-meshheading:17142212...lld:pubmed
pubmed-article:17142212pubmed:meshHeadingpubmed-meshheading:17142212...lld:pubmed
pubmed-article:17142212pubmed:meshHeadingpubmed-meshheading:17142212...lld:pubmed
pubmed-article:17142212pubmed:meshHeadingpubmed-meshheading:17142212...lld:pubmed
pubmed-article:17142212pubmed:meshHeadingpubmed-meshheading:17142212...lld:pubmed
pubmed-article:17142212pubmed:meshHeadingpubmed-meshheading:17142212...lld:pubmed
pubmed-article:17142212pubmed:articleTitleExamination of the rescue effects of folic acid on derangement of the tubo-ovarian ultrastructural architecture caused by methotrexate.lld:pubmed
pubmed-article:17142212pubmed:affiliationDepartment of Obstetrics and Gynecology, Gazi University, Ankara, Turkey.lld:pubmed
pubmed-article:17142212pubmed:publicationTypeJournal Articlelld:pubmed